ChiCTR2000036345 版本V1.1 版本创建时间2020/09/07 04:01:10 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000036345 

最近更新日期:

Date of Last Refreshed on:

2020-08-22 08:36:11 

注册时间:

Date of Registration:

2020-08-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于无创DNA技术评价口腔黏膜癌变风险的前瞻性探索性研究

Public title:

A preliminary prospective study based on non-invasive DNA content analysis to evaluate the risk of oral mucosal carcinogenesis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于无创DNA技术评价口腔黏膜癌变风险的前瞻性探索性研究

Scientific title:

A preliminary prospective study based on non-invasive DNA content analysis to evaluate the risk of oral mucosal carcinogenesis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

施琳俊 

研究负责人:

施琳俊 

Applicant:

Linjun Shi 

Study leader:

Linjun Shi 

申请注册联系人电话:

Applicant telephone:

13917461596

研究负责人电话:

Study leader's telephone:

13917461596

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

19190117@qq.com

研究负责人电子邮件:

Study leader's E-mail:

191909117@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市黄浦区瞿溪路500号8楼口腔黏膜科

研究负责人通讯地址:

上海市黄浦区瞿溪路500号8楼口腔黏膜科

Applicant address:

Department of Oral Mucosal Diseases, 8th Floor, 500 Quxi Road, Huangpu District, Shanghai

Study leader's address:

Department of Oral Mucosal Diseases, 8th Floor, 500 Quxi Road, Huangpu District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学医学院附属第九人民医院

Applicant's institution:

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

研究负责人所在单位:

上海交通大学医学院附属第九人民医院

Affiliation of the Leader:

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SH9H-2020-T246-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海交通大学医学院附属第九人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020-08-21 00:00:00

伦理委员会联系人:

甄红

Contact Name of the ethic committee:

Hong Zhen

伦理委员会联系地址:

上海市黄浦区制造局路639号10号楼5楼

Contact Address of the ethic committee:

5th Floor, Building 8, No. 639, Zhizaoju Road, Huangpu District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学医学院附属第九人民医院

Primary sponsor:

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

研究实施负责(组长)单位地址:

上海市黄浦区瞿溪路500号0楼口腔黏膜病科

Primary sponsor's address:

Department of Oral Mucosal Diseases, 8th Floor, 500 Quxi Road, Huangpu District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

上海

Country:

China

Province:

Shanghai

City:

Shanghai

单位(医院):

上海交通大学医学院附属第九人民医院

具体地址:

上海市黄浦区瞿溪路500号0楼口腔黏膜病科

Institution
hospital:

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

Address:

500 Quxi Road, Huangpu District

经费或物资来源:

上海申康医院发展中心

Source(s) of funding:

Shanghai Hospital Development Center

Target disease:

oral potentially malignant disorders

Target disease code:

研究类型:

预后研究

Study type:

Prognosis study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

基于适用于口腔黏膜癌变的DNA定量分析技术诊断标准,结合流行病学资料、临床损害特征建立OPMD癌变风险评价指标,并以前瞻性试验验证该风险评价指标的效果。  

Objectives of Study:

Based on the diagnostic criteria of DNA quantitative analysis technology applicable to oral mucosal carcinogenesis, combined with epidemiological data and clinical damage characteristics, the OPMD cancer risk evaluation index was established, and the effect of the risk evaluation index was verified by prospective trials.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①临床和病理诊断为红斑、口腔白斑、口腔扁平苔藓、口腔黏膜苔藓样损害及口腔黏膜下纤维性变。
②年龄在18~75周岁。
③能够自愿,如实提供吸烟和饮酒等不良习惯史。
④能够配合细胞刷进行口腔黏膜脱落细胞取样。

Inclusion criteria

①The clinical and pathological diagnosis was erythema, oral leukoplakia, oral lichen planus, oral lichenoid damage and oral submucosal fibrosis.
②Age between 18 and 75 years old.
③Able to provide a history of bad habits such as smoking and drinking truthfully.
④Able to cooperate with cell brush to sample exfoliated oral mucosa cells.

排除标准:

①入组筛选时病理诊断已癌变。
②入组后6个月内即发生癌变。
③妊娠或哺乳期妇女。
④其他口腔黏膜病、精神病患者。

Exclusion criteria:

① The pathological diagnosis was cancer at the time of enrollment.
② Carcinogenesis occurred within 6 months after enrollment.
③ Pregnant or lactating women.
④ Patients with other oral mucosal diseases and mental illnesses.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 2026-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 2021-09-30 00:00:00  

干预措施:

Interventions:

组别:

暴露组

样本量:

67

Group:

exposed group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

非暴露组

样本量:

67

Group:

unexposed group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

上海 

Country:

China 

Province:

Shanghai 

City:

Shanghai 

单位(医院):

上海交通大学医学院附属第九人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

癌变

指标类型:

主要指标

Outcome:

carcinogenesis

Type:

Primary indicator

测量时间点:

入组时

测量方法:

组织病理学显微镜下诊断

Measure time point of outcome:

at the time of enrollment

Measure method:

histopathological diagnosis under microscope

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-08-22 08:36:02